Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2009-01-20
2010-02-23
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S141100, C424S143100, C424S144100, C424S152100, C424S173100, C530S387100, C530S387300, C530S388100, C530S388200, C530S388220, C530S388700, C530S388730
Reexamination Certificate
active
07666422
ABSTRACT:
The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.
REFERENCES:
patent: 5182368 (1993-01-01), Ledbetter et al.
patent: 5354847 (1994-10-01), Liu et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5540926 (1996-07-01), Aruffo et al.
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5597569 (1997-01-01), Siegall et al.
patent: 5674492 (1997-10-01), Armitage et al.
patent: 5677165 (1997-10-01), De Boer et al.
patent: 5801227 (1998-09-01), Fanslow et al.
patent: 5872215 (1999-02-01), Osbourne et al.
patent: 5874082 (1999-02-01), De Boer
patent: 5985847 (1999-11-01), Carson et al.
patent: 6037454 (2000-03-01), Jardieu et al.
patent: 6051228 (2000-04-01), Aruffo et al.
patent: 6054297 (2000-04-01), Carter et al.
patent: 6056959 (2000-05-01), De Boer et al.
patent: 6838261 (2005-01-01), Siegall et al.
patent: 6843989 (2005-01-01), Siegall et al.
patent: 6946129 (2005-09-01), Siegall et al.
patent: 7498032 (2009-03-01), Siegall et al.
patent: 7507414 (2009-03-01), Rosen et al.
patent: 7510711 (2009-03-01), Siegall et al.
patent: 7563445 (2009-07-01), Melief
patent: 2003/0022860 (2003-01-01), Melief et al.
patent: 2005/0008637 (2005-01-01), Siegall et al.
patent: 2006/0074008 (2006-04-01), Senter
patent: WO 94/04570 (1994-03-01), None
patent: WO 95/17202 (1995-06-01), None
patent: WO 96/18413 (1996-06-01), None
patent: WO 97/31025 (1997-08-01), None
patent: WO 98/33810 (1998-08-01), None
patent: WO 98/58678 (1998-12-01), None
patent: WO 99/42075 (1999-08-01), None
patent: WO 00/75348 (2000-12-01), None
patent: WO 2006/128103 (2006-11-01), None
patent: WO 2007/075326 (2007-07-01), None
Bridges et al., “Selective In Vivo Antitumor Effects of Monoclonal Anti-I-A Antibody on a B Cell Lymphoma,” J. Immunol., 1987, 139(12),4242-4249.
Carter et al., “Humanization of an anti-p185HER2 antibody for human cancer therapy,” Proc. Natl. Acad. Sci. USA, 1992, 89, 4285-4289.
Cunningham et al., “Receptor and Antibody Epitopes in Human Growth Hormone Identified by Homolog-Scanning Mutagenesis,” Science, 1989, 243, 1330-1336.
U.S. Appl. No. 11/913,305, filed May 26, 2005, Presta et al.
U.S. Appl. No. 12/302,743, filed May 7, 2009, Siegall et al.
U.S. Appl. No. 12/390,170, filed Feb. 20, 2009, Siegall et al.
Paulie et al., “Monoclonal antibodies to antigens associated with transitional cell carcinoma of the human urinary bladder,”Cancer Immunol. Immunother., 1984, 17, 173-179.
Pellat-Decounynck et al., “Expression of CD28 and CD40 in Human Myeloma Cells: A Comparative Study with Normal Plasma Cells,”Blood, 1994, 84(8), 2597-2603.
www.ncbi.nlm.nih.gov (National Center for Biotechnology Information) GenBank Accession No. A61522, Oct. 15, 1994, 7.5k surfactant-associated protein—human (fragment).
www.ncbi.nlm.nih.gov (National Center for Biotechnology Information) GenBank Protein Accession No. S69899, 1997, Ig heavy chain V region (clone RFTS7H), rheumatoid factor—human.
www.ncbi.nlm.nih.gov (National Center for Biotechnology Information) GenBank Accession No. D50136, Apr. 12, 1995, Mus musculus mRNA for anti-acid phosphatase variable light chain 11, partial cds.
www.ncbi.nlm.nih.gov (National Center for Biotechnology Information) GenBank Protein Accession No. C29380, 1988, Ig kappa chain precursor V region (BC-1004)—mouse (fragment).
www.ncbi.nlm.nih.gov (National Center for Biotechnology Information) GenBank Protein Accession No. S67941, 1997, Ig heavy chain variable region, subgroup I (clone MH52)—human (fragment).
Accession No. W78434, 1998, Antibody light chain directed to HER3 clone 18.
Accession No. Y06716, 1999, Antibody 12B5 single chain Fv (scFv) fragment.
Ada, G., “The coming of age of immunotherapy,” Immunology and Cell Biology, 1999, 77, p. 180-185.
Alessandrini, A. et al., “Coordination of immunoglobulin DJH transcription and D-to-JH rearrangement by promoter-enhancer approximation,” Mol. Cell Biol., 1991, 11(4),2096-2107.
Andersen et al., “Soluble CD40 ligand induces cell cycle progression in primary mantle cell lymphoma,” Blood, 1999, 94(10), Suppl. 1, p. 630a.
Apostolopoulos et al., “MUC1 cross-reactive Gala(1,3)Gal antibodies in humans switch immune response from cellular to humoral,” Nature Medicine, 1998, 4, 315-320.
Armitage et al., “Distinct patterns of inhibition by CD40 mAb of the CD40 ligand-CD40 interaction,” Leukocyte Typing V, Schlossman et al. (eds.), 1995, 1, 551-552.
Becker et al., “Tumor escape mechanisms from immunosurveillance: induction of unresponsiveness in a specific MHC-restricted CD4+ human T cell clone by the autologous MHC class II+ melanoma,” International Immunology, 1993, 5(12), 1501-1508.
Bender et al., Human antibodies and Hybridomas, 1993, 4, 74-79 (Abstract).
Bendig, Methods: A Companion to Methods in Enzymology. 8:83-93, 1995.
Bjorck et al., “Antibodies to distinct epitopes on the CD40 molecule co-operate in stimulation and can be used for the detection of soluble CD40,” Immunology, 1994,83, 430-437.
Bjorck, P. et al., “CD40 antibodies defining distinct epitopes display qualitative differences in their induction of B-cell differentiation,” Immunology, 1996, 87(2), 291-295.
Braesch-Andersen et al., Isolation and characterization of two bladder carcinoma-associated antigens. J. Immunol Methods. Nov. 20, 1986;94(1-2):145-151b.
Bubenik, J. et al., “Monoclonal antibodies against human urinary bladder carcinomas: selectivity and utilization for gamma scintigraphy,” Eur. J. Cancer Clin.Oncol., 1985, 21(6), 701-710.
Buchsbaum et al., “Improved Delivery of Radiolabeled Anti-B1 Monoclonal Antibody to Raji Lymphoma Xenografts by Predosing with Unlabeled Anti-B1 Monoclonal Antibody,” Cacner Research, 1992, 52, 637-642.
Buhmann et al., “CD40-Activated B-cell Chronic Lymphocytic Leukemia Cells for Tumor Immunotherapy: Stimulation of Allogeneic Versus Autologous T Cells Generates Different Types of Effector Cells,” Blood, 1999, 93, p. 1992-2002.
Cattan et al., “The C.B. 17 SCID Mouse Strain as a Model for Human Disseminated Leukemia and Myeloma In Vivo,” Leukemia Research, 1994, 18(7), 513-522.
Caux et al., “Activation of Human Dendritic Cells through CD40 Cross-Linking,” Journal of Experimental Medicine, 1994, 180, p. 1263-1272.
Cella et al., “Ligation of CD40 on Dendritic Cells Triggers Production of High Levels of Interleukin-12 and Enhances T Cell Stimulatory Capacity: T-T Help via APC Activation,” Journal of Experimental Medicine, 1996, 184, p. 747-752.
Challa, A. et al., “Epitope-dependent synergism and antagonism between CD40 antibodies and soluble CD40 ligand for the regulation of CD23 expression and IgE synthesis in human B cells,” Allergy, 1999, 54(6), 576-583.
Charreau et al., “Transgenesis in rats: technical aspects and models”, Transgenic Res. Jul. 1996;5(4):223-234 (Abstract).
Chen et al., “Nucleotide and translated amino acid sequences of cDNA coding for the variable regions of the light and heavy chains of mouse hybridoma antibodies to blood group A and B substances,” J. Biol. Chem., 1987, 262(28), 13579-13583.
Chen et al., “Enhancement And Destruction Of Antibody Function By Somatic Mutation; Unequal Occurrence is Controlled by V Gene Combinational Associations,” EMBO J., 14: 2784-2794, 1995.
Clark, E.A. et al., “Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50,” PNAS U.S.A., 1986, 83(12), 4494-4498.
Clark, (ed.), “Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Application in Man”, 1993. The Alden Press, pp. 4-5.
Colman, “Effects Of
Fell, Jr. Henry Perry
Francisco Joseph A.
Siegall Clay B.
Wahl Alan F.
Gambel Phillip
Seattle Genetics Inc.
Townsend and Townsend / and Crew LLP
LandOfFree
Methods for the treatment of cancer using anti-CD40 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for the treatment of cancer using anti-CD40 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the treatment of cancer using anti-CD40 antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4218403